FASB has drug makers squealing

Big question marks hang over the latest proposals from the Financial Accounting Standards Board, reported here, requiring companies to account for the potential cost of ongoing litigation. As The Wall Street Journal points out, it would give attorneys a licence to print money because they would be able to use the information to force settlements and influence juries. Knowing what lawyers are like, it's a good point. And bad guesswork by companies would leave them vulnerable.Drug companies have been leading the charge against the proposal, claiming there is no way they would know how much those law suits might cost. In their letter to the FASB, Pfizer Inc., Merck & Co., Eli Lilly & Co., Johnson & Johnson, Novartis AG, and Wyeth are reported saying the estimates would be ""highly subjective, subject to huge swings as underlying... [read full story]                    

Add Comment
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies